Does Transient Receptor Potential Vanilloid Type 1 Alleviate or Aggravate Pathological Myocardial Hypertrophy?

Area of Science:

• Cardiovascular Physiology
• Molecular Biology
• Cell Signaling

Background:

• Transient receptor potential vanilloid type 1 (TRPV1) is a non-selective cation channel involved in cardiac stress adaptation and heart disease.
• TRPV1's role in non-neuronal cardiac cells and its specific mechanisms in pathological myocardial hypertrophy require clarification.

Purpose of the Study:

• To summarize the multifaceted role of TRPV1 in the development of pathological myocardial hypertrophy.
• To elucidate the mechanisms underlying TRPV1's involvement, considering both its beneficial and detrimental effects.
• To present novel perspectives from the research team on TRPV1 and myocardial hypertrophy.

Main Methods:

• Literature review and synthesis of existing research on TRPV1 and myocardial hypertrophy.
• Analysis of studies investigating TRPV1's role in alleviating pathological myocardial hypertrophy.
• Examination of studies detailing TRPV1's contribution to the aggravation of pathological myocardial hypertrophy.

Main Results:

• Evidence suggests TRPV1 activation can alleviate pathological myocardial hypertrophy, particularly through sensory nerve stimulation.
• Conversely, some findings indicate TRPV1 may exacerbate myocardial hypertrophy under certain conditions.
• The precise mechanisms and net effect of TRPV1 in myocardial hypertrophy remain complex and context-dependent.

Conclusions:

• TRPV1 exhibits a complex, dual role in pathological myocardial hypertrophy, acting as both a protective and detrimental factor.
• Further research is needed to fully understand TRPV1's mechanisms in myocardial hypertrophy.
• Targeting TRPV1 pathways may offer potential therapeutic strategies for pathological myocardial hypertrophy.